AIA Group Ltd Purchases 15,295 Shares of AbbVie Inc. $ABBV

AIA Group Ltd lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 132.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,837 shares of the company’s stock after buying an additional 15,295 shares during the quarter. AIA Group Ltd’s holdings in AbbVie were worth $6,214,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ABBV. Lindenwold Advisors INC grew its holdings in shares of AbbVie by 1.0% during the 3rd quarter. Lindenwold Advisors INC now owns 15,635 shares of the company’s stock valued at $3,620,000 after purchasing an additional 148 shares during the last quarter. Mirabella Financial Services LLP lifted its stake in AbbVie by 154.7% in the 3rd quarter. Mirabella Financial Services LLP now owns 32,899 shares of the company’s stock valued at $7,602,000 after purchasing an additional 19,980 shares during the last quarter. Farmers National Bank lifted its stake in AbbVie by 66.5% in the 3rd quarter. Farmers National Bank now owns 14,178 shares of the company’s stock valued at $3,283,000 after purchasing an additional 5,664 shares during the last quarter. Hudson Bay Capital Management LP lifted its stake in AbbVie by 24.1% in the 3rd quarter. Hudson Bay Capital Management LP now owns 69,352 shares of the company’s stock valued at $16,058,000 after purchasing an additional 13,466 shares during the last quarter. Finally, Alecta Tjanstepension Omsesidigt boosted its position in AbbVie by 10.5% in the third quarter. Alecta Tjanstepension Omsesidigt now owns 1,158,900 shares of the company’s stock valued at $268,262,000 after buying an additional 110,300 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Activity

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ABBV shares. Berenberg Bank set a $275.00 price target on AbbVie in a research note on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. Finally, Guggenheim restated a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) released new global consumer research and updated educational programs that could support its aesthetics franchise and long‑term revenue diversification. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: Independent valuation and market‑commentary pieces highlight a recent share‑price pullback and renewed debate over AbbVie’s near‑term multiple; these analyses may lead to more analyst revisions but are not a direct operational hit. Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
• Negative Sentiment: FDA approved J&J’s Icotyde, the first oral IL‑23 inhibitor, creating direct competition for Skyrizi; analysts and articles warn Icotyde could capture significant market share because of oral dosing convenience, pressuring AbbVie’s key growth driver. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: multiple outlets report a ~5% intraday drop and continued underperformance vs. peers as investors price in Icotyde competition and reassess AbbVie’s growth outlook. Elevated volume suggests defensive positioning. ABBV Stock Slides 5%: Is J&J’s Icotyde a Threat to Skyrizi?
• Negative Sentiment: Breckenridge launched a generic version of Savella (milnacipran), which introduces additional generic competition in a product AbbVie previously marketed—incremental revenue headwind for that niche pain product. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

AbbVie Stock Down 1.0%

NYSE ABBV opened at $206.32 on Friday. The company has a market capitalization of $364.80 billion, a price-to-earnings ratio of 87.42, a PEG ratio of 0.72 and a beta of 0.34. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a fifty day simple moving average of $223.41 and a 200 day simple moving average of $224.71.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.